CN102958937B - 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物 - Google Patents

作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物 Download PDF

Info

Publication number
CN102958937B
CN102958937B CN201180031069.5A CN201180031069A CN102958937B CN 102958937 B CN102958937 B CN 102958937B CN 201180031069 A CN201180031069 A CN 201180031069A CN 102958937 B CN102958937 B CN 102958937B
Authority
CN
China
Prior art keywords
compound
spiro
difluoromethoxy
disease
ethanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180031069.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102958937A (zh
Inventor
S·F·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combination Therapy Co
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN102958937A publication Critical patent/CN102958937A/zh
Application granted granted Critical
Publication of CN102958937B publication Critical patent/CN102958937B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
CN201180031069.5A 2010-06-24 2011-06-24 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物 Active CN102958937B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
US61/358,209 2010-06-24
PCT/DK2011/000069 WO2011160632A1 (en) 2010-06-24 2011-06-24 Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Publications (2)

Publication Number Publication Date
CN102958937A CN102958937A (zh) 2013-03-06
CN102958937B true CN102958937B (zh) 2016-03-30

Family

ID=44351701

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180031069.5A Active CN102958937B (zh) 2010-06-24 2011-06-24 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物

Country Status (29)

Country Link
US (3) US8980905B2 (enExample)
EP (2) EP3070091B1 (enExample)
JP (2) JP6174997B2 (enExample)
KR (1) KR101864578B1 (enExample)
CN (1) CN102958937B (enExample)
AU (1) AU2011269429B2 (enExample)
BR (1) BR112012032813B1 (enExample)
CA (1) CA2802895C (enExample)
CY (2) CY1117862T1 (enExample)
DK (2) DK3070091T3 (enExample)
ES (2) ES2733092T3 (enExample)
HR (2) HRP20160919T1 (enExample)
HU (2) HUE044301T2 (enExample)
IL (1) IL223329A (enExample)
LT (2) LT2585469T (enExample)
MX (1) MX2012014131A (enExample)
MY (1) MY157481A (enExample)
NZ (1) NZ603895A (enExample)
PL (2) PL2585469T3 (enExample)
PT (2) PT3070091T (enExample)
RS (2) RS55104B1 (enExample)
RU (1) RU2583787C2 (enExample)
SG (1) SG186140A1 (enExample)
SI (2) SI2585469T1 (enExample)
TR (1) TR201909709T4 (enExample)
TW (1) TWI507410B (enExample)
UA (1) UA109140C2 (enExample)
WO (1) WO2011160632A1 (enExample)
ZA (1) ZA201209031B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104822392B (zh) * 2012-11-30 2017-09-08 利奥制药有限公司 抑制活化的t‑细胞中il‑22表达的方法
DK3157930T3 (en) * 2014-06-23 2019-01-21 Leo Pharma As PROCEDURES FOR THE PREPARATION OF HETEROCYCLIC 1,3-BENZODIOXOL COMPOUNDS
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN114085234B (zh) * 2015-12-18 2024-12-17 联合疗法公司 用于制备1,3-苯并间二氧杂环戊烯杂环化合物的方法
DK3642210T3 (da) * 2017-06-20 2024-12-09 Union Therapeutics As Fremgangsmåder til fremstilling af heterocykliske 1,3-benzodioxolforbindelser
JP7203846B2 (ja) 2017-12-15 2023-01-13 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
RS64672B1 (sr) 2019-01-15 2023-11-30 Union Therapeutics As Formulacije tableta sa modifikovanim oslobađanjem koje sadrže inhibitore fosfodiesteraze
PH12022550189A1 (en) * 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Ezh2 inhibition in combination therapies for the treatment of cancers
MD4003532T2 (ro) 2019-07-24 2025-01-31 Constellation Pharmaceuticals Inc Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
EP4313043A1 (en) 2021-03-22 2024-02-07 UNION therapeutics A/S Treatment of hidradenitis suppurativa with orismilast
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771794A1 (en) * 1995-05-19 1997-05-07 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
CN1219171A (zh) * 1996-05-20 1999-06-09 达尔文发现有限公司 苯并呋喃甲酰胺及其治疗用途
EP0943613A1 (en) * 1996-11-19 1999-09-22 Kyowa Hakko Kogyo Kabushiki Kaisha Oxygenic heterocyclic compounds
WO2008104175A2 (en) * 2007-02-28 2008-09-04 Leo Pharma A/S Novel phosphodiesterase inhibitors
CN101631792A (zh) * 2007-02-28 2010-01-20 利奥制药有限公司 新的磷酸二酯酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1046939C (zh) * 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EA014956B1 (ru) * 2004-12-17 2011-04-29 ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений
AU2012357106A1 (en) * 2011-12-21 2014-06-05 Leo Pharma A/S [1,2,4]triazolopyridines and their use as phospodiesterase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0771794A1 (en) * 1995-05-19 1997-05-07 Kyowa Hakko Kogyo Co., Ltd. Oxygen-containing heterocyclic compounds
CN1219171A (zh) * 1996-05-20 1999-06-09 达尔文发现有限公司 苯并呋喃甲酰胺及其治疗用途
EP0943613A1 (en) * 1996-11-19 1999-09-22 Kyowa Hakko Kogyo Kabushiki Kaisha Oxygenic heterocyclic compounds
WO2008104175A2 (en) * 2007-02-28 2008-09-04 Leo Pharma A/S Novel phosphodiesterase inhibitors
CN101631792A (zh) * 2007-02-28 2010-01-20 利奥制药有限公司 新的磷酸二酯酶抑制剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
METABOLISM OF FLUORINE-CONTAINING DRUGS;B Kevin Park,等;《annual review of pharmacology and toxicology》;20010401;第41卷(第1期);第447页第2-3段 *
α-Fluorinated Ethers, Thioethers, and Amines: Anomerically Biased Species;Frederic Leroux,等;《Chem. Rev.》;20050301;第105卷(第3期);第848页-第849页6.3.3节 *

Also Published As

Publication number Publication date
HUE044301T2 (hu) 2019-10-28
EP2585469A1 (en) 2013-05-01
IL223329A (en) 2017-01-31
LT2585469T (lt) 2016-10-10
BR112012032813A2 (pt) 2016-11-08
EP2585469B1 (en) 2016-05-25
US9273064B2 (en) 2016-03-01
NZ603895A (en) 2014-10-31
BR112012032813B1 (pt) 2022-02-01
KR101864578B1 (ko) 2018-06-07
HK1182699A1 (zh) 2013-12-06
PT2585469T (pt) 2016-08-29
PT3070091T (pt) 2019-07-22
WO2011160632A1 (en) 2011-12-29
CY1122201T1 (el) 2020-11-25
ES2584055T3 (es) 2016-09-23
SI3070091T1 (sl) 2019-08-30
CA2802895C (en) 2019-05-21
UA109140C2 (uk) 2015-07-27
KR20130038341A (ko) 2013-04-17
LT3070091T (lt) 2019-07-25
ES2733092T3 (es) 2019-11-27
HUE030081T2 (en) 2017-04-28
CY1117862T1 (el) 2017-05-17
DK3070091T3 (da) 2019-07-08
TWI507410B (zh) 2015-11-11
MX2012014131A (es) 2013-01-29
JP2013529602A (ja) 2013-07-22
TR201909709T4 (tr) 2019-07-22
US9637499B2 (en) 2017-05-02
HRP20160919T1 (hr) 2016-10-07
EP3070091B1 (en) 2019-04-17
US8980905B2 (en) 2015-03-17
US20160022657A1 (en) 2016-01-28
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
EP3070091A1 (en) 2016-09-21
PL2585469T3 (pl) 2017-07-31
AU2011269429B2 (en) 2015-07-09
US20130123291A1 (en) 2013-05-16
IL223329A0 (en) 2013-02-03
JP2016164168A (ja) 2016-09-08
SI2585469T1 (sl) 2016-11-30
TW201206940A (en) 2012-02-16
DK2585469T3 (en) 2016-08-29
SG186140A1 (en) 2013-01-30
RS55104B1 (sr) 2016-12-30
RU2583787C2 (ru) 2016-05-10
ZA201209031B (en) 2014-02-26
RS58945B1 (sr) 2019-08-30
HRP20191136T1 (hr) 2019-09-20
JP6174997B2 (ja) 2017-08-02
CA2802895A1 (en) 2011-12-29
US20150111915A1 (en) 2015-04-23
PL3070091T3 (pl) 2019-09-30
MY157481A (en) 2016-06-15
RU2013103079A (ru) 2014-07-27

Similar Documents

Publication Publication Date Title
CN102958937B (zh) 作为磷酸二酯酶抑制剂的苯并二氧杂环戊烯或苯并二氧杂环庚烯杂环化合物
US8338431B2 (en) Phosphodiesterase inhibitors
TW200946531A (en) HSP90 inhibitors
MX2011009314A (es) Compuesto de quinoxalina.
KR20140105598A (ko) [1,2,4]트리아졸로피리딘 및 포스포디에스테라제 억제제로서의 이의 용도
CN101631792A (zh) 新的磷酸二酯酶抑制剂
HK1182699B (en) Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
TWI432439B (zh) 新穎磷酸二酯酶抑制劑

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1182699

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1182699

Country of ref document: HK

TR01 Transfer of patent right

Effective date of registration: 20210705

Address after: Dane Heller Rupp

Patentee after: Combination therapy Co.

Address before: Denmark and Rupp

Patentee before: LEO PHARMA A/S

TR01 Transfer of patent right